Since STAT3 is highly activated in macrophages within the tumor microenvironment, combinational treatment of anti-gp130 and anti-PD-1 for T cell re-activation, or targeted drug for tumor cells, could be an optimal regimen for cancer treatment, avoiding the dilemma of insufficient elimination of tumors by STAT3 monotherapy. This evidence concerns the gene STAT3 and neoplasm.